Abstract
Systemic sclerosis (SSc) is an autoimmune connective tissue disease with multisystem involvement. An increased incidence of cancer in SSc patients compared with the general population has been reported in several reports. Our aims in this study were to determine the most common malignancies and to investigate the possible risk factors for the development of malignancy in patients with SSc. Three hundred forty SSc patients from 13 centers were included to the study. Data of the patients were obtained by evaluating their medical records retrospectively. A total of 340 patients with SSc were evaluated. Twenty-five of the patients had 19 different types of malignancy. Bladder cancer was the most common type of cancer with four patients and was followed by breast cancer with three patients, and cervix cancer and ovarian cancer with two patients each. Other types of cancers such as squamous cell skin cancer, adenocancer with an unknown origin, multiple myeloma, chronic myeloid leukemia, papillary thyroid cancer, larynx cancer, non-small cell lung cancer, follicular type non-Hodgkin lymphoma (NHL), endometrium cancer, colon cancer, uterus cancer, neuroendocrine tumor, glioblastoma multiforme, and soft tissue sarcoma were diagnosed in one patient each. The only cancer type that showed an association with cyclophosphamide dose was bladder carcinoma. Other malignancies did not show a correlation with age, sex, smoking, type and duration of the disease, autoantibodies, organ involvement, and dose and duration of cyclophosphamide therapy. Cancer may develop in any organ in patients with SSc. Continuous screening of the patients during a follow-up period is necessary for the early detection of the tumor development.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69:1809–15
Szekanecz É, Szamosi S, Horváth Á, Németh Á, Juhász B, Szántó J et al (2012) Malignancies associated with systemic sclerosis. Autoimmun Rev 11:852–5
Siau K, Laversuch CJ, Creamer P, O’Rourke KP (2011) Malignancy in scleroderma patients from southwest England: a population-based cohort study. Rheumatol Int 31:641–5
Wooten M (2008) Systemic sclerosis and malignancy: a review of the literature. South Med J 101:59–62
Olesen AB, Svaerke C, Farkas DK, Sørensen HT (2010) Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 163:800–6
Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer induced in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65:1913–21
Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C et al (2013) Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52:143–54
Hashimato A, Arinuma Y, Nagai T, Tanaka S, Matsui T, Tohma S et al (2012) Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med 51:1683–8
Askling J, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–14
Kinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78(1A):44–9
Kuwana M, Fujii T, Mimori T, Kaburaki J (1996) Enhancement of anti-DNA topoisomerase I antibody response after lung cancer in patients with systemic sclerosis: a report of two cases. Arthritis Rheum 39:686–91
Rothfield N, Kurtzman S, Vazgues-Abad D, Charron C, Daniels L, Greenberg B (1988) Association of antitopoisomerase I with cancer. Arhritis Rheum 31:378–85
Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K (2000) Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 19:123–26
Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24:165–70
Shah AA, Casciola-Rosen L (2015) Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening. Curr Opin Rheumatol 27(6):563–70. doi:10.1097/BOR.0000000000000222
Rittner G, Schwanitz G, Baur MP, Black CM, Welsh KI, Kühnl P et al (1988) Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet 81:64–70
Wolff DJ, Needleman BW, Wasserman SS, Schwartz S (1991) Spontaneous and clastogen induced chromosomal breakage in scleroderma. J Rheumatol 18:837–40
Avouac J, Borderie D, Ekindjian OG, Kahan A, Allanore Y (2010) High DNA oxidative damage in systemic sclerosis. J Rheumatol 37:2540–47
Martins EP, Fuzzi HT, Kayser C, Alarcon RT, Rocha MG, Chauffaille ML et al (2010) Increased chromosome damage in systemic sclerosis in skin fibroblasts. Scand J Rheumatol 39:398–401
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Kaşifoğlu, T., Yaşar Bilge, Ş., Yıldız, F. et al. Risk factors for malignancy in systemic sclerosis patients. Clin Rheumatol 35, 1529–1533 (2016). https://doi.org/10.1007/s10067-016-3288-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-016-3288-8